VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...

A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...

While pericytes are important regulators of capillary function and homeostasis, the lack of specific markers has hampered the ...

Humanity achieved a fateful milestone last year. The European Union’s Copernicus Climate Change Service has officially ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.

Tampa General Hospital led the nation in transplant surgeries for the first time in its history. Surgeons performed a hospital record 889 transplants in 2024, up from 756 procedures the previous year ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...